Variable prenatal stress results in impairments of sustained attention and inhibitory response control in a 5-choice serial reaction time task in rats

Neuroscience

Volumn 218, Issue , 2012, Pages 126-137

  Wilson, C A ^a   Schade, R ^a   Terry, A V ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Atomoxetine; Attention deficit; Glutamate; Impulsivity compulsivity; Schizophrenia

Indexed keywords

ATOMOXETINE; DIZOCILPINE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; NORADRENALIN;

5 CHOICE SERIAL REACTION TIME TASK; ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; FEMALE; IMPULSIVENESS; MENTAL PERFORMANCE; MENTAL TASK; NONHUMAN; PRENATAL STRESS; PRIORITY JOURNAL; RAT; REACTION TIME; SCHIZOPHRENIA;

ANIMALS; ATTENTION; DISEASE MODELS, ANIMAL; FEMALE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; SCHIZOPHRENIA; STRESS, PSYCHOLOGICAL;

EID: 84863775259     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.05.040     Document Type: Article

References (60)

1. Amitai N., Markou A. Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-d-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia. Biol Psychiatry 2010, 68(1):5-16.
2. Amitai N., Markou A. Comparative effects of different test day challenges on performance in the 5-choice serial reaction time task. Behav Neurosci 2011, 125(5):764-774.
3. Bangs M.E., Emslie G.J., Spencer T.J., Ramsey J.L., Carlson C., Bartky E.J., Busner J., Duesenberg D.A., Harshawat P., Kaplan S.L., Quintana H., Allen A.J., Sumner C.R. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol 2007, 17(4):407-420.
4. Bari A., Dalley J.W., Robbins T.W. The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats. Nat Protoc 2008, 3(5):759-767.
5. Birkett P., Sigmundsson T., Sharma T., Toulopoulou T., Griffiths T.D., Reveley A., Murray R. Reaction time and sustained attention in schizophrenia and its genetic predisposition. Schizophr Res 2007, 95(1-3):76-85.
6. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., Morin S.M., Gehlert D.R., Perry K.W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002, 27:699-711.
7. Caballero J., Nahata M.C. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. Clin Ther 2003, 25(12):3065-3083.
8. Capizzi M., Sanabria D., Correa A. Dissociating controlled from automatic processing in temporal preparation. Cognition 2012, 123(2):293-302.
9. Carboni E., Tanda G.L., Frau R., Chiara Di. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 1990, 55:1067-1070.
10. Carli M., Robbins T.W., Evenden J.L., Everitt B.J. Effects of lesions to ascending noradrenergic neurons on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav Brain Res 1983, 9:361-380.
11. Carli M., Samanin R. Serotonin2 receptor agonists and serotonergic anorectic drugs affect rats' performance differently in a five-choice serial reaction time task. Psychopharmacology (Berl) 1992, 106:228-234.
12. Chamberlain S.R., Del Campo N., Dowson J., Müller U., Clark L., Robbins T.W., Sahakian B.J. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry 2007, 62:977-984.
13. Chang K., Nayar D., Howe M., Rana M. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder. J Child Adolesc Psychopharmacol 2009, 19(5):547-551.
14. Davis EP, Sandman CA (2012) Prenatal psychobiological predictors of anxiety risk in preadolescent children. Psychoneuroendocrinology. doi:10.1016/j.psyneuen.2011.12.016.
15. Friedman J.I., Carpenter D., Lu J., Fan J., Tang C.Y., White L., Parrella M., Bowler S., Elbaz Z., Flanagan L., Harvey P.D. A pilot study of adjunctive atomoxetine treatment to seconds-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol 2008, 28(1):59-63.
16. Grizenko N., Shayan Y.R., Polotskaia A., Ter-Stepanian M., Joober R. Relation of maternal stress during pregnancy to symptom severity and response to treatment in children with ADHD. Rev Psychiatr Neurosci 2008, 33(1):10-16.
17. Hagan J.J., Jones D.N. Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr Bull 2005, 31:830-853.
18. Han G., Klimes-Dougan B., Jepsen S., Ballard K., Nelson M., Houri A., Kumra S., Cullen K. Selective neurocognitive impairments in adolescents with major depressive disorder. J Adolesc 2012, 35(1):11-20.
19. Higgins G.A., Breysse N. Rodent model of attention: the 5-Choice serial reaction time task. Curr Protoc Pharmacol 2008, 5.49.1-5.49.20.
20. Javitt D.C., Schoepp D., Kalivas P.W., Volkow N.D., Zarate C., Merchant K., Bear M.F., Umbricht D., Hajos M., Potter W.Z., Lee C.M. Translating glutamate: from pathophysiology to treatment. Sci Transl Med 2011, 3(102). 102mr2.
21. Kapoor A., Dunn E., Kostaki A., Andrews M.H., Matthews S.G. Fetal programming of hypothalamo-pituitary-adrenal function: prenatal stress and glucocorticoids. J Physiol 2006, 572(1):31-44.
22. Kelly D.L., Buchanan R.W., Boggs D.L., McMahon R.P., Dickinson D., Nelson M., Gold J.M., Ball M.P., Feldman S., Liu F., Conley R.R. A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry 2009, 70(4):518-525.
23. Kinney D.K., Munir K.M., Crowley D.J., Miller A.M. Prenatal stress and risk for autism. Neurosci Biobehav Rev 2008, 32(8):1519-1532.
24. Kinnunen A.K., Koenig J.I., Bilbe G. Repeated variable prenatal stress alters pre- and postsynaptic gene expression in the rat frontal pole. J Neurochem 2003, 86:736-748.
25. Koenig J.I., Elmer G.I., Shepard P.D., Lee P.R., Mayo C., Joy B., Hercher E., Brady D.L. Prenatal exposure to a repeated variable stress paradigm elicits behavioral and neuroendocrinological changes in the adult offspring: potential relevance to schizophrenia. Behav Brain Res 2005, 156:251-261.
26. Koffarnus M.N., Katz J.L. Response requirement and increases in accuracy produced by stimulant drugs in a 5-choice serial reaction-time task in rats. Psychopharmacology (Berl) 2011, 213(4):723-733.
27. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995, 13(1):9-19.
28. Lee J., Park S. The role of stimulus salience in CPT-AX performance of schizophrenia patients. Schizophr Res 2006, 81:191-197.
29. Lee P.R., Brady D.L., Shapiro R.A., Dorsa D.M., Koenig J.I. Prenatal stress generates deficits in rat social behavior: reversal by oxytocin. Brain Res 2007, 1156:152-167.
30. Lewis D.A., Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 2002, 25:409-432.
31. Linnet K.M., Dalsgaard S., Obel C., Wisborg K., Henriksen T.B., Rodriguez A., Kotimaa A., Moilanen I., Thomsen P.H., Olsen J., Jarvelin M.R. Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence. Am J Psychiatry 2003, 160:1028-1040.
32. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997, 17:141-150.
33. Marco E.M., Macrì S., Laviola G. Critical age windows for neurodevelopmental psychiatric disorders: evidence from animal models. Neurotox Res 2011, 19(2):286-307.
34. Markham J.A., Taylor A.R., Taylor S.B., Bell D.B., Koenig J.I. Characterization of the cognitive impairments induced by prenatal exposure to stress in the rat. Front Behav Neurosci 2010, 4:173.
35. Markham J.A., Koenig J.I. Prenatal stress: role in psychotic and depressive diseases. Psychopharmacology 2011, 214(1):89-106.
36. Michelson D., Adler L., Spencer T., Reimherr F.W., West S.A., Allen A.J., Kelsey D., Wernicke J., Dietrich A., Milton D. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003, 53:112-120.
37. Middlemore-Risher M.L., Buccafusco J.J., Terry A.V. Repeated exposures to low-level chlorpyrifos results in impairments in sustained attention and increased impulsivity in rats. Neurotoxicol Teratol 2010, 32(4):415-424.
38. Mirjana C., Baviera M., Invernizzi R.W., Balducci C. The serotonin 5-HT2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex. Neuropsychopharmacology 2004, 29:1637-1647.
39. Navarra R., Graf R., Huang Y., Logue S., Comery T., Hughes Z., Day M. Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(1):34-41.
40. Paine T.A., Carlezon W.A. Effects of antipsychotic drugs on MK-801-induced attentional and motivational deficits in rats. Neuropharmacology 2009, 56(4):788-797.
41. Park S.H., Noh J.C., Kim J.H., Lee J., Park J.Y., Lee Y.R., Kim C.H., Lee K.H. Interactive effects of background facial emotion stimulus and target salience on sustained attention performance in schizophrenia. Schizophr Res 2012, 135(1-3):90-94.
42. Paterson N.E., Ricciardi J., Wetzler C., Hanania T. Sub-optimal performance in the 5-choice serial reaction time task in rats was sensitive to methylphenidate, atomoxetine and d-amphetamine, but unaffected by the COMT inhibitor tolcapone. Neurosci Res 2011, 69(1):41-50.
43. Phillips M.L., Drevets W.C., Rauch S.L., Lane R. Neurobiology of emotion perception II: implications for major psychiatric disorders. Biol Psychiatry 2003, 54:515-528.
44. Riccio C.A., Waldrop J.J., Reynolds C.R., Lowe P. Effects of stimulants on the continuous performance test (CPT): implications for CPT use and interpretation. J Neuropsychiatry Clin Neurosci 2001, 13:326-335.
45. Rice F., Jones I., Thapar A. The impact of gestational stress and prenatal growth on emotional problems in offspring: a review. Acta Psychiatr Scand 2007, 115:171-183.
46. Robbins T.W. The 5-choice serial reaction time task: behavioral pharmacology and functional neurochemistry. Psychopharmacology (Berl) 2002, 163:362-380.
47. Robinson E.S., Eagle D.M., Mar A.C., Bari A., Banerjee G., Jiang X., Dalley J.W., Robbins T.W. Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat. Neuropsychopharmacology 2008, 33:1028-1037.
48. Rung J.P., Carlsson A., Rydén Markinhuhta K., Carlsson M.L. (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29(5):827-832.
49. Sacco K.A., Creeden C., Reutenauer E.L., Vessicchio J.C., Weinberger A.H., George T.P. Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia. Schizophr Res 2009, 107(2-3):332-333.
50. Sagvolden T., Johansen E.B., Aase H., Russell V.A. A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. Behav Brain Sci 2005, 28(3):397-419.
51. Smith J.W., Gastambide F., Gilmour G., Dix S., Foss J., Lloyd K., Malik N., Tricklebank M. A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory. Psychopharmacology (Berl) 2011, 217(2):255-269.
52. Spauwen J., Krabbendam L., Lieb R., Wittchen H.U., van Os J. Early maternal stress and health behaviours and offspring expression of psychosis in adolescence. Acta Psychiatr Scand 2004, 110:356-364.
53. Swanson C.J., Perry K.W., Koch-Krueger S., Katner J., Svensson K.A., Bymaster F.P. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 2006, 50:755-760.
54. Terry A.V., Buccafusco J.J., Schade R.F., Vandenhuerk L., Callahan P.M., Beck W.D., Hutchings E.J., Chapman J.M., Li P., Bartlett M.G. The nicotine metabolite, cotinine, attenuates glutamate (NMDA) antagonist-related effects on the performance of the five choice serial reaction time task (5C-SRTT) in rats. Biochem Pharmacol 2012, 83(7):941-951.
55. van Os J., Selten J. Prenatal exposure to maternal stress and subsequent schizophrenia. The May 1940 invasion of The Netherlands. Br J Psychiatry 1998, 172:324-326.
56. Weinstock M. The potential influence of maternal stress hormones on development and mental health of the offspring. Brain Behav Immun 2005, 19:296-308.
57. Wilson C., Terry A.V. Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development. Clin Schizophr Relat Psychosis 2010, 4(2):124-137.
58. Wykes T., Reeder C., Corner J. The prevalence and stability of an executive processing deficit, response inhibition, in people with chronic schizophrenia. Schizophr Res 2000, 46(2-3):241-253.
59. Young J.W., Powell S.B., Risbrough V., Marston H.M., Geyer M.A. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 2009, 122(2):150-202.
60. Zeiner P., Gjevik E., Weidle B. Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder. Acta Paediatr 2011, 100(9):1258-1261.